E-Mail
The precise choice of treatment for breast cancer depends upon the status of the hormone receptors (for oestrogen and progesterone). Their conventional determination by means of immunohistochemistry (IHC) is associated with a certain error rate, which can be reduced by adding genomic data. Even conventional statistics can bring about a notable improvement but now it is possible to use decision theory to optimally combine diagnostic findings, particularly where they are contradictory. This is the finding of a recent study conducted by MedUni Vienna under the leadership of Wolfgang Schreiner from the Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS). The methodology has applications way beyond breast cancer and can be deployed in all circumstances where it is necessary to draw conclusions from many findings at the same time, even if the findings are contradictory.
Using decision theory for precise choice of breast cancer treatment
The precise choice of treatment for breast cancer depends upon the status of the hormone receptors (for estrogen and progesterone). Their conventional determination by means of immunohistochemistry (IHC) is associated with a certain error rate, which can be reduced by adding genomic data.
Even conventional statistics can bring about a notable improvement but now it is possible to use decision theory to optimally combine diagnostic findings, particularly where they are contradictory.
This is the finding of a recent study conducted by MedUni Vienna under the leadership of Wolfgang Schreiner from the Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS).
E-Mail
Modern immunotherapeutic anti-cancer drugs support a natural mechanism of the immune system to inhibit the growth of cancer cells. They dock onto a specific receptor of the killer cell and prevent it from being switched off by the cancer cells. This is a complex molecular process, which is known but has not yet been fully understood. In a molecular dynamics study conducted by the group led by medical information scientist Wolfgang Schreiner and gynaecologists Heinz Kölbl and Georg Pfeiler from MedUni Vienna, working with biosimulation expert Chris Oostenbrink from the University of Natural Resources and Applied Life Sciences (Boku) Vienna, has now, for the first time, analysed this mechanism for the drugs nivolumab and pembrolizumab. It was found that tiny molecular motions are of key significance. The study has been published in the leading journal
Ein unermüdlicher Helfer pnp.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pnp.de Daily Mail and Mail on Sunday newspapers.